---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-012086"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T17:32:47.820041+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma Q3 net income falls 36% to $0.8M; revenue $15.6M

## Summary
- Q3 revenue $15.6M, down 8.4% YoY from $17.1M; operating income $1.0M vs $1.7M.
- Net income $0.8M ($0.03 diluted EPS) vs $1.2M ($0.04) in prior-year quarter.
- Nine-month revenue $43.0M, down 7.6%; net income $2.3M vs $3.5M.
- Revenue decline attributed to normalization of customer safety stock from COVID-19 pandemic.
- Two largest contract manufacturing customers still represent ~91% of total revenue.

## SEC filing metadata
- accession: 0001437749-22-012086
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 5.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774922012086/0001437749-22-012086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774922012086/inbp20220511_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-012086
- JSON: https://secwatch.observer/filing/0001437749-22-012086.json
- Plain text: https://secwatch.observer/filing/0001437749-22-012086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.